Morgan Stanley Pharming Group N.V. Transaction History
Morgan Stanley
- $1.27 Trillion
- Q2 2024
A detailed history of Morgan Stanley transactions in Pharming Group N.V. stock. As of the latest transaction made, Morgan Stanley holds 2,800 shares of PHAR stock, worth $23,324. This represents 0.0% of its overall portfolio holdings.
Number of Shares
2,800
Previous 2,800
-0.0%
Holding current value
$23,324
Previous $30,000
23.33%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding PHAR
# of Institutions
7Shares Held
67.7KCall Options Held
0Put Options Held
0-
Silverberg Bernstein Capital Management LLC Armonk, NY41.1KShares$342,4460.31% of portfolio
-
Cowen Prime Advisors LLC22.5KShares$187,0910.09% of portfolio
-
Ubs Group Ag789Shares$6,5720.0% of portfolio
-
Advisor Group Holdings, Inc. Phoenix, AZ568Shares$4,7310.0% of portfolio
-
Farther Finance Advisors, LLC San Francisco, CA11Shares$910.0% of portfolio
About Pharming Group N.V.
- Ticker PHAR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 65,241,400
- Market Cap $543M
- Description
- Pharming Group N.V., a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the tre...